KR100978418B1 - 비타민-표적된 영상제 - Google Patents

비타민-표적된 영상제 Download PDF

Info

Publication number
KR100978418B1
KR100978418B1 KR1020047017608A KR20047017608A KR100978418B1 KR 100978418 B1 KR100978418 B1 KR 100978418B1 KR 1020047017608 A KR1020047017608 A KR 1020047017608A KR 20047017608 A KR20047017608 A KR 20047017608A KR 100978418 B1 KR100978418 B1 KR 100978418B1
Authority
KR
South Korea
Prior art keywords
vitamin
receptor
folate
binding
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047017608A
Other languages
English (en)
Korean (ko)
Other versions
KR20040104686A (ko
Inventor
크리스토퍼폴 레아몬
매튜에이. 파커
Original Assignee
엔도사이트, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔도사이트, 인코포레이티드 filed Critical 엔도사이트, 인코포레이티드
Publication of KR20040104686A publication Critical patent/KR20040104686A/ko
Application granted granted Critical
Publication of KR100978418B1 publication Critical patent/KR100978418B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
KR1020047017608A 2002-05-06 2003-05-06 비타민-표적된 영상제 Expired - Fee Related KR100978418B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37857102P 2002-05-06 2002-05-06
US60/378,571 2002-05-06
PCT/US2003/014379 WO2003092742A1 (en) 2002-05-06 2003-05-06 Vitamin-targeted imaging agents

Publications (2)

Publication Number Publication Date
KR20040104686A KR20040104686A (ko) 2004-12-10
KR100978418B1 true KR100978418B1 (ko) 2010-08-26

Family

ID=29401611

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047017608A Expired - Fee Related KR100978418B1 (ko) 2002-05-06 2003-05-06 비타민-표적된 영상제

Country Status (18)

Country Link
US (5) US7128893B2 (enExample)
EP (4) EP1501551B1 (enExample)
JP (1) JP4801348B2 (enExample)
KR (1) KR100978418B1 (enExample)
CN (2) CN101648028B (enExample)
AT (1) ATE448799T1 (enExample)
AU (1) AU2003239383C1 (enExample)
CA (1) CA2484345C (enExample)
CY (1) CY1114733T1 (enExample)
DE (1) DE60330135D1 (enExample)
DK (3) DK2151250T3 (enExample)
ES (4) ES2500922T3 (enExample)
IL (1) IL164811A (enExample)
NZ (1) NZ536467A (enExample)
PT (2) PT2260875E (enExample)
SI (2) SI2260875T1 (enExample)
WO (1) WO2003092742A1 (enExample)
ZA (1) ZA200408664B (enExample)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7875612B2 (en) 2001-04-24 2011-01-25 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
MXPA03010035A (es) 2001-05-02 2004-06-30 Purdue Research Foundation Tratamiento y diagnostico de enfermedades mediadas por macrofagos.
US8043603B2 (en) * 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
NZ536467A (en) * 2002-05-06 2006-11-30 Endocyte Inc Vitamin-targeted imaging agents
KR20040106547A (ko) * 2002-05-15 2004-12-17 엔도사이트, 인코포레이티드 비타민-마이토마이신 공액체
CA2512867C (en) * 2003-01-27 2014-08-26 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
EP1622646B1 (en) * 2003-05-06 2012-08-08 Purdue Research Foundation Treatment of lupus targeting the macrophages or the folate receptor
DE602004017452D1 (de) * 2003-05-30 2008-12-11 Purdue Research Foundation Diagnoseverfahren für atherosklerose
US8288557B2 (en) * 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
JP2008519859A (ja) * 2004-11-10 2008-06-12 ユニバーシティー オブ サウス フロリダ 標的化した薬物送達のための白金錯体
RU2007128036A (ru) * 2004-12-23 2009-01-27 Пердью Рисерч Фаундейшн (Us) Способ получения изображения позитронно-эмиссионной томографией
EP1863816B1 (en) * 2005-03-16 2014-06-25 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
WO2007006041A2 (en) * 2005-07-05 2007-01-11 Purdue Research Foundation Imaging and therapeutic method using monocytes
EP2382995A3 (en) 2005-08-19 2013-09-25 Endocyte, Inc. Ligand conjugates of Vinca alkaloids, analogs and derivatives
BRPI0615354A2 (pt) 2005-08-19 2011-05-17 Endocyte Inc conjugado de liberação de fármaco de ligação de receptor, composição farmacêutica que o compreende, bem como seu uso
US8795633B2 (en) 2005-09-23 2014-08-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
EP2087337A4 (en) * 2006-11-03 2010-09-08 Purdue Research Foundation METHOD AND DEVICE FOR EX-VIVO FLOW CYTOMETRY
AU2008213702B2 (en) * 2007-02-07 2014-04-24 Purdue Research Foundation Positron emission tomography imaging method
WO2008101231A2 (en) * 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
WO2008098788A2 (en) * 2007-02-16 2008-08-21 Ktb Tumorforschungsgesellschaft Mbh Receptor and antigen targeted prodrug
CN104127878A (zh) 2007-03-14 2014-11-05 恩多塞特公司 结合配体连接的微管溶素递药缀合物
PT2146944E (pt) 2007-04-11 2014-03-11 Merck & Cie Processo para a preparação de folatos marcados com 18f
JP5710246B2 (ja) * 2007-04-11 2015-04-30 メルク エ カンパニー 診断用画像及び放射線治療用の葉酸複合体及び対応する金属キレート錯体
EP2164525A2 (en) * 2007-05-25 2010-03-24 Purdue Research Foundation Method of imaging localized infections
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CA2690943A1 (en) * 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
EP3838298B1 (en) * 2007-08-17 2025-02-26 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
JP2011500835A (ja) 2007-10-25 2011-01-06 エンドサイト，インコーポレイテッド チューブリシン類および調製プロセス
US20100272675A1 (en) * 2007-11-15 2010-10-28 Endocyte, Inc. Method of administering conjugates
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US8426398B2 (en) 2009-01-13 2013-04-23 Emory University Conjugates of noscapine and folic acid and their use in treating cancer
CA2753975C (en) 2009-03-02 2017-09-26 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
WO2010102238A1 (en) * 2009-03-05 2010-09-10 Purdue Research Foundation Method for early imaging of atherosclerosis
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
SI2556171T1 (sl) 2010-04-05 2016-03-31 Prognosys Biosciences, Inc. Prostorsko kodirane biološke analize
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
WO2011133868A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Conformationally restricted dinucleotide monomers and oligonucleotides
US10913767B2 (en) 2010-04-22 2021-02-09 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
EP2683410A2 (en) 2011-03-08 2014-01-15 Access Pharmaceuticals, Inc. Targeted nanocarrier systems for delivery of actives across biological membranes
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
CN103732595B (zh) 2011-08-17 2017-02-08 默克及其合伙人公司 叶酸的白蛋白‑结合实体缀合物
JP6228551B2 (ja) 2012-01-03 2017-11-08 インビクタス オンコロジー プライベート リミテッド リガンド−標的指向分子およびその方法
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
EP2822386B1 (en) * 2012-02-29 2021-05-05 Purdue Research Foundation Folate receptor alpha binding ligands
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US20150174273A1 (en) * 2012-07-25 2015-06-25 Emory University Imaging and therapeutic methods for treating parathyroid tumors
CA2887727A1 (en) 2012-10-16 2014-04-24 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
EP3901280B1 (en) 2012-10-17 2025-03-12 10x Genomics Sweden AB Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
KR101551232B1 (ko) 2012-10-26 2015-09-10 한국원자력연구원 Ｎ3ｓ1형의 새로운 킬레이터가 접합된 폴레이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 진단 또는 치료용 조성물
HK1211493A1 (en) 2012-11-15 2016-05-27 恩多塞特公司 Conjugates for treating diseases caused by psma expressing cells
WO2014150943A1 (en) * 2013-03-15 2014-09-25 Purdue Research Foundation Asthma imaging and therapy
CN105849275B (zh) 2013-06-25 2020-03-17 普罗格诺西斯生物科学公司 检测样品中生物靶标的空间分布的方法和系统
EP3415489A1 (en) 2013-10-18 2018-12-19 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
SG10201803618RA (en) * 2013-11-14 2018-06-28 Endocyte Inc Compounds for positron emission tomography
EP3574924B1 (en) 2013-11-19 2021-01-06 Purdue Research Foundation Patient selection method for inflammation
US10426753B2 (en) 2014-04-03 2019-10-01 Invictus Oncology Pvt. Ltd. Supramolecular combinatorial therapeutics
EP3160514B1 (en) * 2014-06-27 2024-07-31 Reiley Pharmaceuticals, Inc. Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging
US20160166679A1 (en) * 2014-12-12 2016-06-16 Purdue Research Foundation Method of treatment using folate conjugates and tyrosine kinase inhibitors
AU2015364508A1 (en) 2014-12-18 2017-07-06 Alnylam Pharmaceuticals, Inc. ReversirTM compounds
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US10053478B2 (en) 2015-01-09 2018-08-21 Reiley Pharmaceuticals, Inc. COX-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
CA2982146A1 (en) 2015-04-10 2016-10-13 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
EP3324980B1 (en) 2015-07-17 2021-11-10 Alnylam Pharmaceuticals, Inc. Multi-targeted single entity conjugates
US10420850B2 (en) * 2015-08-14 2019-09-24 Endocyte, Inc. Method of imaging with a chelating agent
KR20240161696A (ko) 2015-12-04 2024-11-12 10엑스 제노믹스, 인크. 핵산 분석을 위한 방법 및 조성물
JP2019515880A (ja) 2016-03-16 2019-06-13 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 炭酸無水酵素ｉｘ阻害剤抱合体およびその使用
WO2017161170A1 (en) * 2016-03-16 2017-09-21 Purdue Research Foundation Carbonic anhydrase ix targeting agents and methods
US20170296679A1 (en) 2016-04-18 2017-10-19 Intuitive Surgical Operations, Inc. Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands
US11524082B2 (en) 2017-08-22 2022-12-13 Purdue Research Foundation FBSA-based therapeutic and radioimaging conjugates targeting carbonic anhydrase positive cancers
EP3781215A4 (en) 2018-04-17 2021-12-29 Endocyte, Inc. Methods of treating cancer
MX2020011570A (es) 2018-05-07 2020-11-24 Alnylam Pharmaceuticals Inc Administracion extrahepatica.
AU2019350765A1 (en) 2018-09-28 2021-05-27 Alnylam Pharmaceuticals, Inc. Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated ocular diseases
EP3969052A1 (en) 2019-05-17 2022-03-23 Alnylam Pharmaceuticals Inc. Oral delivery of oligonucleotides
CN120097930A (zh) 2019-05-20 2025-06-06 因多塞特股份有限公司 制备psma缀合物的方法
WO2021086982A2 (en) 2019-10-28 2021-05-06 Beckman Coulter, Inc. Compounds for the identification of microbial classes and uses thereof
EP4055165A1 (en) 2019-11-06 2022-09-14 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
CA3160329A1 (en) 2019-11-06 2021-05-14 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery
US12399123B1 (en) 2020-02-14 2025-08-26 10X Genomics, Inc. Spatial targeting of analytes
US12281357B1 (en) 2020-02-14 2025-04-22 10X Genomics, Inc. In situ spatial barcoding
ES2981265T3 (es) 2020-06-08 2024-10-08 10X Genomics Inc Métodos para determinar un margen quirúrgico y métodos de uso del mismo
US11981960B1 (en) 2020-07-06 2024-05-14 10X Genomics, Inc. Spatial analysis utilizing degradable hydrogels
US20230257745A1 (en) 2020-07-10 2023-08-17 Alnylam Pharmaceuticals, Inc. Circular siRNAs
IL313194A (en) 2020-10-30 2024-07-01 Tod SPEER Oligonucleotide-based treatments and their uses
AU2021411579A1 (en) 2020-12-31 2023-07-13 Alnylam Pharmaceuticals, Inc. Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
WO2022147223A2 (en) 2020-12-31 2022-07-07 Alnylam Pharmaceuticals, Inc. 2'-modified nucleoside based oligonucleotide prodrugs
US20240165250A1 (en) * 2021-01-08 2024-05-23 Lycia Therapeutics, Inc. Bifunctional Folate Receptor Binding Compounds
EP4582555A3 (en) 2021-06-03 2025-10-22 10X Genomics, Inc. Methods, compositions, kits, and systems for enhancing analyte capture for spatial analysis
WO2023283403A2 (en) 2021-07-09 2023-01-12 Alnylam Pharmaceuticals, Inc. Bis-rnai compounds for cns delivery
KR20240036604A (ko) 2021-07-14 2024-03-20 리시아 테라퓨틱스, 인크. Asgpr 세포 표면 수용체 결합 화합물 및 접합체
MX2024000981A (es) 2021-07-21 2024-02-12 Alnylam Pharmaceuticals Inc Composiciones de acido ribonucleico de interferencia (arni) de gen diana asociado con trastorno metabolico y sus metodos de uso.
KR20240101590A9 (ko) 2021-10-15 2025-12-10 알닐람 파마슈티칼스 인코포레이티드 간외 전달 irna 조성물 및 이를 이용하는 방법
JP2025516680A (ja) 2022-05-13 2025-05-30 アルナイラム ファーマシューティカルズ， インコーポレイテッド 一本鎖ループオリゴヌクレオチド
WO2024006999A2 (en) 2022-06-30 2024-01-04 Alnylam Pharmaceuticals, Inc. Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
JP2025532985A (ja) 2022-09-30 2025-10-03 アルナイラム ファーマシューティカルズ， インコーポレイテッド 修飾二本鎖ｒｎａ剤
WO2024238385A2 (en) 2023-05-12 2024-11-21 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
WO2025064660A2 (en) 2023-09-21 2025-03-27 Alnylam Pharmaceuticals, Inc. Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2816110A (en) 1956-11-23 1957-12-10 Merck & Co Inc Methods for the production of substituted pteridines
US5140104A (en) 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs
US5175343A (en) * 1985-01-14 1992-12-29 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5242679A (en) * 1985-01-14 1993-09-07 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
NZ217821A (en) 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US5053493A (en) * 1987-04-02 1991-10-01 Centocor Cardiovascular Imaging Partners, L.P. Method for labeling antibodies with a metal ion
CA2101942C (en) 1991-02-08 2001-01-30 Richard T. Dean Technetium-99m labeled polypeptides for imaging
US7238340B1 (en) * 1991-11-27 2007-07-03 Cis Bio International Monoamine, diamide, thiol-containing metal chelating agents
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US5159079A (en) 1991-12-20 1992-10-27 Eli Lilly And Company 2-piperidones as intermediates for 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids
US6022966A (en) 1993-11-22 2000-02-08 Neorx Corporation Pretargeting methods and compounds
DE4311022C2 (de) * 1993-03-31 1996-07-11 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner vom Typ S¶3¶N¶2¶ für radioaktive Isotope und deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel
DE4311021A1 (de) * 1993-03-31 1994-10-27 Diagnostikforschung Inst Bifunktionelle Chelatbildner, deren Technetium- und Rhenium-Komplexe, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende radiopharmazeutische Mittel
DE4310999C2 (de) * 1993-03-31 1996-07-18 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner vom Typ XN¶1¶S¶1¶X' für radioaktive Isotope und deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel
DE4311023C2 (de) * 1993-03-31 1996-05-02 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner von Typ XN¶1¶S¶1¶O¶1¶ für radioaktive Isotope, deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel
DE4425781A1 (de) * 1994-07-14 1996-01-18 Schering Ag Technetium-Sulfonamid-Komplexe, deren Verwendung, diese enthaltende pharmazeutische Mittel, sowie Verfahren zur Herstellung der Komplexe und Mittel
US6083480A (en) * 1997-05-01 2000-07-04 Diatide, Inc. Calcitonin receptor binding reagents
US6093382A (en) * 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US6323313B1 (en) * 1999-06-01 2001-11-27 The University Of Washington Annexin derivative with endogenous chelation sites
ES2518926T3 (es) * 2000-06-02 2014-11-05 Board Of Regents, The University Of Texas System Conjugados de etilendicisteína y un análogo de glucosa
MXPA03010035A (es) * 2001-05-02 2004-06-30 Purdue Research Foundation Tratamiento y diagnostico de enfermedades mediadas por macrofagos.
NZ536467A (en) * 2002-05-06 2006-11-30 Endocyte Inc Vitamin-targeted imaging agents
CA2512867C (en) * 2003-01-27 2014-08-26 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
EP1622646B1 (en) * 2003-05-06 2012-08-08 Purdue Research Foundation Treatment of lupus targeting the macrophages or the folate receptor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging

Also Published As

Publication number Publication date
EP1501551B1 (en) 2009-11-18
EP2258401A2 (en) 2010-12-08
AU2003239383B2 (en) 2008-10-16
PT2260875E (pt) 2014-06-25
US7128893B2 (en) 2006-10-31
CN101648028A (zh) 2010-02-17
DK2258401T3 (da) 2014-10-13
CA2484345C (en) 2015-09-29
ES2472423T3 (es) 2014-07-01
EP1501551A1 (en) 2005-02-02
IL164811A (en) 2012-06-28
US20140065068A1 (en) 2014-03-06
EP2258401B1 (en) 2014-07-09
HK1141440A1 (en) 2010-11-12
KR20040104686A (ko) 2004-12-10
JP4801786B2 (ja) 2011-10-26
US8834842B2 (en) 2014-09-16
US20040033195A1 (en) 2004-02-19
CA2484345A1 (en) 2003-11-13
CN100528241C (zh) 2009-08-19
EP2258401A3 (en) 2011-08-24
DK2260875T3 (da) 2014-06-30
US8865126B2 (en) 2014-10-21
EP2151250A1 (en) 2010-02-10
ATE448799T1 (de) 2009-12-15
US20070031334A1 (en) 2007-02-08
CN101648028B (zh) 2012-11-21
US20090324499A1 (en) 2009-12-31
CN1662263A (zh) 2005-08-31
ES2336780T3 (es) 2010-04-16
EP2151250B1 (en) 2013-10-02
SI2151250T1 (sl) 2014-02-28
JP2011012066A (ja) 2011-01-20
EP2260875B1 (en) 2014-04-23
WO2003092742A1 (en) 2003-11-13
CY1114733T1 (el) 2016-12-14
ES2500922T3 (es) 2014-10-01
AU2003239383C1 (en) 2009-03-19
EP2260875A2 (en) 2010-12-15
JP4801348B2 (ja) 2011-10-26
JP2006501149A (ja) 2006-01-12
EP1501551A4 (en) 2006-01-11
ES2438008T3 (es) 2014-01-15
US8313728B2 (en) 2012-11-20
PT2151250E (pt) 2013-12-09
SI2260875T1 (sl) 2014-07-31
DE60330135D1 (de) 2009-12-31
ZA200408664B (en) 2007-04-25
DK2151250T3 (da) 2013-12-16
US7862798B2 (en) 2011-01-04
NZ536467A (en) 2006-11-30
AU2003239383A1 (en) 2003-11-17
EP2260875A3 (en) 2011-08-24
US20130237687A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
KR100978418B1 (ko) 비타민-표적된 영상제
US12178892B2 (en) Compounds for positron emission tomography
JPH11510787A (ja) 腫瘍画像化法および組成物
JP4801786B6 (ja) ビタミンを標的とした造影剤
KR101551232B1 (ko) Ｎ3ｓ1형의 새로운 킬레이터가 접합된 폴레이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 진단 또는 치료용 조성물
HK1141440B (en) Vitamin-targeted imaging agents

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20130808

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20140806

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20150805

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20160808

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20170809

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210821

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210821

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000